Variant Summary
- HGVS
- —
- Variant Type(s)
- —
- Evidence Items
- 6
Evidence Level Distribution
Level B: 1Level D: 5
Evidence Items
Showing CIViC evidence rows where gene = NRG1 and variant = Expression.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Lapatinib | 4 |
| D | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Patritumab | 4 |
| D | Predictive | Supports | Sensitivity/Response | Ovarian Cancer | Seribantumab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Cisplatin,Carboplatin,Gemcitabine,Paclitaxel | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Anti-ErbB3 Monoclonal Antibody AV-203 | 3 |